Trial Profile
An Open-label, Single-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093 in Subjects With Various Degrees of Renal Impairment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Eslicarbazepine acetate (Primary)
- Indications Renal impairment
- Focus Pharmacokinetics
- Sponsors Bial
- 27 Jul 2017 Results of a post-hoc pooled analysis of safety data from NCT00957684, NCT00957047, NCT00957372 NCT00988429, NCT02281422, NCT02281526 and NCT01422720 studies published in the Drug Safety
- 05 Nov 2014 New trial record